8 August 2024
HEALTHTECH RANK: 6
REVENUE 2023 ($000): $63,360
STAFF EMPLOYED: 287
VERTICAL: Biotech Therapeutic
OWNERSHIP: Public
FORMED: 2008
“I founded AROA with a mission to unlock regenerative healing for everybody. Our core technology AROA ECM, is sourced from the forestomach of sheep. Containing over 150 proteins important to the healing process, the tissue acts as a bioscaffold, allowing healthy new tissue to form. That is the building block for all our complex wound and soft tissue reconstruction products.
Obtaining market entry and gathering clinical evidence were critical in the earlier stages. From day one, we focused on the world’s largest healthcare market – the US. After gaining FDA approval for our first product, Endoform, we entered the US market in 2013 and haven’t looked back.
Today, AROA has four product families, over 6.5 million product applications worldwide, regulatory approval in more than 50 countries, and 287 talented people supporting the business.
We’re always looking to innovate and have identified ways to improve the manufacturing process, which lowers production costs and enables more patients to access the benefits of regenerative healing.
Taking an idea from concept to commercialisation involves lots of hard work and willingness to keep going, even when you hit stumbling blocks. You’ve got to think creatively and just persevere, keeping your end goal in sight.”
– Brian Ward, Founder & Chief Executive Officer